Scinai Immunotherapeutics Ltd • SCNI

Capital at risk.

About Scinai Immunotherapeutics Ltd
Ticker
info
SCNI
Trading on
info
NASDAQ
ISIN
info
US09073Q3039
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Amir Reichman M.B.A., M.Sc.
Headquarters
info
Jerusalem BioPark, Jerusalem, undefined, Israel, undefined
Employees
info
31
Website
info
scinai.com
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Metrics
BasicAdvanced
Market cap
info
$3.7M
P/E ratio
info
0.29
EPS
info
$4.00
Dividend Yield
info
0.00%
Beta
info
1.66
Forward P/E ratio
info
0
EBIDTA
info
$-6.7M
Ex dividend date
info
-
Price & volume
Market cap
info
$3.7M
Average daily volume
info
0M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0.29
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0.29
Price to sales
info
3.2
Price to book
info
1.79
Earnings
EPS
info
$4.00
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-6.7M
Revenues (TTM)
info
$1.1M
Revenues per share (TTM)
info
$0.87
Technicals
Beta
info
1.66
52-week High
info
$3.99
52-week Low
info
$0.86
50-day moving average
info
$1.24
200-day moving average
info
$2.11
Short ratio
info
0.19
Short %
info
0.40%
Management effectiveness
ROE (TTM)
info
17.92%
ROA (TTM)
info
-39.56%
Profit margin
info
448.39%
Gross profit margin
info
$-1.7M
Operating margin
info
-486.81%
Growth
Quarterly earnings growth (YoY)
info
87.20%
Quarterly revenue growth (YoY)
info
36.10%
Share stats
Outstanding Shares
info
3.2M
Float
info
5.28B
Insiders %
info
10.30%
Institutions %
info
4.74%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$700.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$12.39
-
-
Q3 • 24Beat
-$2.64
-
-
Q4 • 24Beat
$4.31
-
-
Q1 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.4M
$-1.5M
-400.78%
Q1 • 25
$0.4M
$-2.1M
-534.80%
Q2 • 25
0.00%
33.44%
33.44%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$11.8M
$4M
33.63%
Q1 • 25
$11.8M
$4M
33.63%
Q2 • 25
0.00%
0.00%
0.00%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-1.3M
-
$0.8M
$-1.3M
Q1 • 25
$-1.3M
-
$0.8M
$-1.3M
Q2 • 25
-
-
0.00%
-0.00%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Scinai Immunotherapeutics Ltd share?
Collapse

Scinai Immunotherapeutics Ltd shares are currently traded for undefined per share.

How many shares does Scinai Immunotherapeutics Ltd have?
Collapse

Scinai Immunotherapeutics Ltd currently has 3.2M shares.

Does Scinai Immunotherapeutics Ltd pay dividends?
Collapse

No, Scinai Immunotherapeutics Ltd doesn't pay dividends.

What is Scinai Immunotherapeutics Ltd 52 week high?
Collapse

Scinai Immunotherapeutics Ltd 52 week high is $3.99.

What is Scinai Immunotherapeutics Ltd 52 week low?
Collapse

Scinai Immunotherapeutics Ltd 52 week low is $0.86.

What is the 200-day moving average of Scinai Immunotherapeutics Ltd?
Collapse

Scinai Immunotherapeutics Ltd 200-day moving average is $2.11.

Who is Scinai Immunotherapeutics Ltd CEO?
Collapse

The CEO of Scinai Immunotherapeutics Ltd is Amir Reichman M.B.A., M.Sc..

How many employees Scinai Immunotherapeutics Ltd has?
Collapse

Scinai Immunotherapeutics Ltd has 31 employees.

What is the market cap of Scinai Immunotherapeutics Ltd?
Collapse

The market cap of Scinai Immunotherapeutics Ltd is $3.7M.

What is the P/E of Scinai Immunotherapeutics Ltd?
Collapse

The current P/E of Scinai Immunotherapeutics Ltd is 0.29.

What is the EPS of Scinai Immunotherapeutics Ltd?
Collapse

The EPS of Scinai Immunotherapeutics Ltd is $4.00.

What is the PEG Ratio of Scinai Immunotherapeutics Ltd?
Collapse

The PEG Ratio of Scinai Immunotherapeutics Ltd is null.

What do analysts say about Scinai Immunotherapeutics Ltd?
Collapse

According to the analysts Scinai Immunotherapeutics Ltd is considered a buy.